Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC35A4 is a member of the solute carrier family 35 of nucleotide sugar transporters, localized to intracellular organelles such as the Golgi and the mitochondrial inner membrane[1][4][5]. It is predicted to function as a transporter, facilitating the import of CDP-ribitol across organellar membranes, and is notably required for maintaining cellular respiration and for the regulation of protein translation in response to stress[1][4][5]. It does not transport CMP-sialic acid, UDP-galactose, or UDP-N-acetylglucosamine[5][6]. Gene mutations have been implicated in severe neurodevelopmental disorders known as developmental and epileptic encephalopathies[1]. SLC35A4 belongs to a large family of nucleotide sugar transporters, which are essential for glycoprotein and glycolipid biosynthesis[2]. There are no currently known drugs targeting this transporter, and its implication in disease is primarily through loss-of-function mutations.
Not established for therapeutic agents; protein mediates cellular uptake of CDP-ribitol into intracellular compartments
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable UDP-sugar transporter protein SLC35A4 (SLC35A4).